This Article Full Text Full Text (PDF) All Versions of this Article: 39/7/2148    most recent STROKEAHA.107.510818v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Merino, J. G. Articles by Warach, S. Search for Related Content PubMed PubMed Citation Articles by Merino, J. G. Articles by Warach, S. Related Collections Acute Cerebral Infarction Computerized tomography and Magnetic Resonance Imaging Thrombolysis

(Stroke. 2008;39:2148.)
© 2008 American Heart Association, Inc.

Research Letters

Reperfusion Half-Life

A Novel Pharmacodynamic Measure of Thrombolytic Activity

José G. Merino, MD, MPhil; Lawrence L. Latour, PhD; Li An, PhD; Amie W. Hsia, MD; Dong-Wha Kang, MD Steven Warach, MD, PhD

From the Section on Stroke Diagnostics and Therapeutics (J.G.M., L.L.L., L.A., S.W.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md; the Washington Hospital Center Stroke Center (A.W.H.), Washington, DC; and the Department of Neurology (D.W.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Correspondence to José G. Merino, MD, MPhil, Suburban Hospital Stroke Program, 8600 Old Georgetown Rd, Bethesda, MD 20814. E-mail merinoj{at}ninds.nih.gov

Background and Purpose— We hypothesized that the probability of reperfusion can be modeled by an exponential decay (ie, half-life) function and that this reperfusion half-life is decreased by thrombolytic treatment.

Methods— Serial perfusion MRI scans were evaluated for evidence of reperfusion in intravenous tissue plasminogen activator-treated (n=45) and untreated (n=103) patients. The cumulative probability of reperfusion for each group was fit with exponential decay functions. The resulting reperfusion half-life (ie, the time it takes half the sample to reperfuse) was calculated.

Results— In untreated patients, a monoexponential decay function fit the data well (R²=0.95) with a half-life of 29.1 hours. In tissue plasminogen activator-treated patients, the data were best fit with a biexponential decay function (R²=0.99) that had a fast and a slow component. The fast component is attributable to tissue plasminogen activator therapy and has a half-life of 0.71 hours, whereas the slow component was similar to that of the untreated group. Approximately 3.5 hours after the start of treatment, the effect of tissue plasminogen activator on the probability of reperfusion was negligible.

Conclusion— The probability of reperfusion can be well described by the reperfusion half-life. Determination of the fast component reperfusion half-life may be an approach to compare the relative potency of different thrombolytic agents.

Key Words: MRI • reperfusion • stroke • thrombolytic therapy